Maxim Group set a $3.00 price objective on Pluristem Therapeutics, Inc. (NASDAQ:PSTI) in a report issued on Wednesday morning. The firm currently has a buy rating on the biotechnology company’s stock.
Several other brokerages have also recently commented on PSTI. HC Wainwright reissued a buy rating and set a $3.50 price target on shares of Pluristem Therapeutics in a research report on Wednesday, September 6th. ValuEngine cut shares of Pluristem Therapeutics from a sell rating to a strong sell rating in a research report on Friday, September 1st. Seaport Global Securities reissued a buy rating and set a $5.00 price target on shares of Pluristem Therapeutics in a research report on Friday, October 6th. Finally, Zacks Investment Research cut shares of Pluristem Therapeutics from a hold rating to a sell rating in a research report on Friday, September 22nd. Two research analysts have rated the stock with a sell rating and four have given a buy rating to the company’s stock. The stock presently has an average rating of Hold and a consensus target price of $4.38.
Shares of Pluristem Therapeutics (NASDAQ PSTI) opened at $1.65 on Wednesday.
ILLEGAL ACTIVITY WARNING: “Maxim Group Reiterates $3.00 Price Target for Pluristem Therapeutics, Inc. (PSTI)” was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this news story on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this news story can be viewed at https://www.com-unik.info/2017/11/04/maxim-group-reiterates-3-00-price-target-for-pluristem-therapeutics-inc-psti.html.
Hedge funds have recently modified their holdings of the company. Heritage Investors Management Corp bought a new stake in shares of Pluristem Therapeutics in the 3rd quarter valued at about $113,000. Jane Street Group LLC raised its holdings in shares of Pluristem Therapeutics by 62.4% in the 1st quarter. Jane Street Group LLC now owns 108,830 shares of the biotechnology company’s stock valued at $134,000 after purchasing an additional 41,796 shares during the period. Finally, Renaissance Technologies LLC raised its holdings in shares of Pluristem Therapeutics by 9.1% in the 1st quarter. Renaissance Technologies LLC now owns 1,553,800 shares of the biotechnology company’s stock valued at $1,911,000 after purchasing an additional 129,000 shares during the period. 4.54% of the stock is currently owned by institutional investors.
Pluristem Therapeutics Company Profile
Pluristem Therapeutics Inc is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company’s lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome.
What are top analysts saying about Pluristem Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Pluristem Therapeutics Inc. and related companies.